Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472801 | 0.90 | NPC1 (0.48) | SMN1; SMN2LMNAS1PR2S1PR1S1PR3 | |
| SCHEMBL22472750 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAS1PR2S1PR1S1PR3 | |
| SCHEMBL22472796 | 0.82 | FAAH (0.46) | SMN1; SMN2LMNAS1PR2S1PR1S1PR3 | |
| SCHEMBL25581688 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2LMNAS1PR2S1PR1S1PR3 | |
| SCHEMBL25581632 | 0.79 | PPARA (0.36) | NPC1MAPTRAB9A | |
| SCHEMBL25581687 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAS1PR2S1PR1S1PR3 | |
| SCHEMBL22472789 | 0.78 | CA12 (0.36) | SMN1; SMN2LMNATP53HTT | |
| SCHEMBL22472808 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAS1PR2S1PR1S1PR3 | |
| SCHEMBL22472800 | 0.75 | ADORA2A (0.45) | SMN1; SMN2MAPTMAPK1HTT | |
| SCHEMBL22472804 | 0.75 | MAPK14 (0.43) | SMN1; SMN2LMNANPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | SMN1; SMN2 13/4885LMNA 1223/4885S1PR2 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.